Compatibility «Edarbi Klo» and «Noliprel A forte»

• Interactions Edarbi Klo with Noliprel A forte

  • Dangerous interactions
    • ⓘ Clinical research data show that double blockade of the RAAS as a result of the combined use of ACE inhibitors, ARA II or aliskiren leads to an increase in the incidence of adverse events such as arterial hypotension, hyperkalemia and decreased renal function (including acute renal failure), compared with situations where only one drug acting on the RAAS is used (see sections 'Pharmacodynamics', 'Contraindications' and 'Special instructions').
    • ⓘ The use of ACE inhibitors in combination with angiotensin II receptor antagonists (ARA II) is contraindicated in patients with diabetic nephropathy (see the section 'Contraindications').
    • ⓘ Double blockade of RAAS ARA II, ACE inhibitors or aliskiren is associated with an increased risk of hypotension, hyperkalemia and changes in renal function (including acute renal failure) compared to monotherapy.
    • ⓘ Some drugs or drugs of other pharmacological classes may increase the risk of hyperkalemia: aliskiren and aliskiren‑containing drugs, potassium salts, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists (ARA II), heparin, immunosuppressants such as cyclosporine or tacrolimus, trimethoprim, drugs containing co-trimoxazole (trimethoprim + sulfamethoxazole).
    • ⓘ In patients with established atherosclerotic disease, heart failure or diabetes mellitus with target organ damage, simultaneous therapy with ACE inhibitor and ARA II is associated with a higher incidence of arterial hypotension, syncope, hyperkalemia and deterioration of renal function (including acute renal failure) compared with the use of only one drug that affects the RAAS.
    • ⓘ ACE inhibitors (C09A) + angiotensin ii receptor antagonists => Are associated with an increased risk of arterial hypotension, syncope, hyperkalemia and impaired renal function (in pm acute renal failure) compared with monotherapy.
    • ⓘ Functional renal insufficiency, which can occur against the background of taking diuretics, especially 'loop' ones, with the combined use of metformin increases the risk of lactic acidosis.
    • ⓘ Dehydration of the body while taking diuretic drugs increases the risk of acute renal failure, especially when using high doses of iodine-containing contrast agents.
    • ⓘ In patients receiving diuretics, especially in patients with hypovolemia and/or reduced salt concentrations, at the beginning of perindopril therapy, there may be an excessive decrease in blood pressure, the risk of development, which can be reduced by discontinuing the diuretic, replenishing the loss of fluid or salts before starting perindopril therapy, as well as prescribing perindopril at a low dose with a further gradual increase.
    • ⓘ When using diuretics in the case of congestive heart failure, an ACE inhibitor should be prescribed at a very low dose, possibly after reducing the dose of a potassium-sparing diuretic used simultaneously.
    • ⓘ Indapamide (C03BA11) + Thiazide diuretics (C03A) => Increases the likelihood of hypokalemia. The effect of thiazide diuretics is enhanced. (Dangerous combinations, careful correction of the K+ content in the blood is shown)The likelihood of hypokalemia increases. The effect of thiazide diuretics is enhanced. (Dangerous combinations, careful correction of the K+ content in the blood is shown)The likelihood of hypokalemia increases. The effect of thiazide diuretics is enhanced. (Dangerous combinations, careful correction of the K+ content in the blood is shown)The likelihood of hypokalemia increases. The effect of thiazide diuretics is enhanced. (Dangerous combinations, careful correction of the K+ content in the blood is shown)The likelihood of hypokalemia increases. The effect of thiazide diuretics is enhanced. (Dangerous combinations, careful correction of the K+ content in the blood is shown)The likelihood of hypokalemia increases. The effect of thiazide diuretics is enhanced. (Dangerous combinations, careful correction of the K+ content in the blood is shown)The likelihood of hypokalemia increases. The effect of thiazide diuretics is enhanced. (Dangerous combinations, careful correction of the K+ content in the blood is shown)The likelihood of hypokalemia increases. The effect of thiazide diuretics is enhanced. (Dangerous combinations, careful correction of the K+ content in the blood is shown)The likelihood of hypokalemia increases. The effect of thiazide diuretics is enhanced. (Dangerous combinations, careful correction of the K+ content in the blood is shown)The likelihood of hypokalemia increases. The effect of thiazide diuretics is enhanced. (Dangerous combinations, careful correction of the K+ content in the blood is shown)The likelihood of hypokalemia increases. The effect of thiazide diuretics is enhanced. (Dangerous combinations, careful correction of the K+ content in the blood is shown).
    • ⓘ Patients taking diuretics, especially those who have recently started treatment, may sometimes experience an excessive decrease in blood pressure after starting therapy with perindopril erbumin.
    • ⓘ The use of a diuretic may further increase the risk of lithium toxicity.
    • ⓘ In the elderly, patients with insufficient BCC (in pm receiving diuretic therapy) or with impaired renal function, the combined use of NSAIDs, including selective COX-2 inhibitors, with ACE inhibitors, including perindopril, may lead to deterioration of renal function, including possible acute renal failure.
    • ⓘ In patients receiving diuretics, especially with excessive excretion of fluid and / or electrolytes, at the beginning of perindopril therapy, an excessive decrease in blood pressure may be observed, the risk of which can be reduced by discontinuing the diuretic, replenishing fluid loss (intravenous infusion of 0.9% sodium chloride solution), as well as using perindopril in lower doses.
    • ⓘ When using diuretics in the case of CHF, an ACE inhibitor should be prescribed at a low dose, possibly after reducing the dose of a potassium-sparing diuretic used simultaneously.
  • Negative interactions
    • ⓘ Blood pressure should be monitored and, if necessary, doses of antihypertensive drugs should be adjusted.
    • ⓘ Some drugs or classes of drugs may increase the incidence of hyperkalemia: aliskiren, potassium salts, potassium‑sparing diuretics, ACE inhibitors, ARA II, NSAIDs, heparins, immunosuppressants (such as cyclosporine or tacrolimus), trimethoprim and drugs containing co-trimoxazole (sulfamethoxazole + trimethoprim).
    • ⓘ Co-therapy with ACE inhibitors and angiotensin receptor antagonists.
    • ⓘ If the patient needs extracorporeal therapy, the possibility of using another type of dialysis membrane or another class of antihypertensive drugs should be considered.
    • ⓘ Combination of therapy with ACE inhibitors and ARA II.
    • ⓘ The use of double blockade of the RAAS (for example, in the case of combined use of ACE inhibitors and ARA II) should be limited to isolated cases with strict control of renal function, potassium content in blood plasma and blood pressure (see section 'Special instructions').
    • ⓘ Antihypertensive agents and vasodilators.
    • ⓘ The use of indapamide can sum up or potentiate the effect of other antihypertensive drugs.
    • ⓘ In limited controlled studies comparing the effects of indapamide in combination with other antihypertensive drugs with the effects of other antihypertensive drugs used as monotherapy, there were no noticeable changes in the nature or frequency of adverse reactions associated with combination therapy.
    • ⓘ Blood pressure should be monitored and, if necessary, the doses of antihypertensive drugs should be adjusted.
    • ⓘ The possibility of hypotensive effects can be minimized by reducing the dose or canceling the diuretic, or increasing salt intake before starting treatment with perindopril.
    • ⓘ Double blockade (for example, with simultaneous use of an ACE inhibitor with ARA II) should be limited to individual cases with careful monitoring of renal function, potassium content and blood pressure.
    • ⓘ Concomitant use of ACE inhibitors with angiotensin II receptor antagonists.
    • ⓘ Antihypertensive and vasodilating agents.
    • ⓘ It enhances the antihypertensive effect of ACE inhibitors, blood pressure monitoring is required and, if necessary, dose adjustment of antihypertensive drugs.
    • ⓘ In hypertension in patients with hypovolemia or reduced salt concentrations during diuretic therapy, diuretics should either be discontinued before the use of an ACE inhibitor (while a potassium-sparing diuretic may later be re-prescribed), or an ACE inhibitor should be prescribed at a low dose with a further gradual increase.
    • ⓘ Indapamide and Chlortalidone belong to the same pharmaceutical group: Thiazide diuretics.
    • ⓘ Indapamide and Chlortalidone belong to the same pharmaceutical group: Sulfonamides.
    • ⓘ However, the bioavailability of perindoprilate was reduced by diuretics, which was associated with a decrease in ACE inhibition in plasma.
    • ⓘ In patients receiving diuretics that remove fluid and / or salts, at the beginning of Perindopril therapy, there may be a marked decrease in blood pressure, the risk of which can be reduced by discontinuing diuretics, replenishing the loss of fluid or salts before starting Perindopril therapy, as well as using Perindopril at a low dose with a further gradual increase.
    • ⓘ In hypertension in patients receiving diuretics, especially those that remove fluid and/or salts, diuretics should either be discontinued before the use of an ACE inhibitor (while a potassium-sparing diuretic may be prescribed again later), or an ACE inhibitor should be prescribed at a low dose with a further gradual increase.
    • ⓘ The additional use of thiazide diuretics against the background of the combined use of lithium preparations and ACE inhibitors increases the already existing risk of lithium intoxication.
  • No interactions
    • ⓘ Concomitant diuretics do not affect the rate and degree of absorption and excretion of perindopril.
  • Positive interactions
    • ⓘ The antihypertensive effect of perindopril may be enhanced when combined with other antihypertensive drugs, vasodilators, nitrates of short and prolonged action.
  • Unclear interactions
    • ⓘ Potassium-sparing diuretics.
    • ⓘ Diuretics.
    • ⓘ Potassium-containing diuretics (eplerenone, spironolactone).

Decoding the colors of interactions and contraindications

Dangerous	—	a pronounced negative interaction or contraindication.
Negative	—	negative interaction or side effect that may reduce effectiveness.
Positive	—	the interaction can SOMETIMES be used as a positive (often a dose adjustment is needed), or it is an indication.
No	—	the drugs do NOT interact, which is separately indicated in the instructions.
Unclear	—	the system failed to pre-assess the danger.

Video instruction

▶

Look at ▶Youtube

Additional information

• Kiberis checks interactions and evaluates drug compatibility for free online right in the instructions thanks to the latest artificial intelligence technologies. The accuracy of finding is more than 95%, the accuracy of the hazard assessment is more than 80%. The online medical service takes into account all the drug groups of the selected drugs and all their components. And since the database contains 25,000 drugs with detailed instructions, not every pharmacologist can compete with our artificial intelligence. List of popular interactions.
• Why do I need to
  • Avoid dangerous prescriptions for your patients.
  • Check the contraindications.
  • Evaluate the safety of therapy in the treatment of children.
  • See the compatibility of drugs with alcohol (enter it as a drug).
  • Point the doctor to the found interaction - you may need to adjust the therapy.
  • Do you need an API for interactions/drug analogues for your project? Write to us.
• The use of information about interactions is only possible as an introduction. This information should not be used to adjust therapy without consulting a specialist.
• The article is written: artificial intelligence Kiberis
• Sources: official instructions for medicines and their active substances, as well as inter-group interactions described in medical studies and textbooks.
• Total analyzed: 170,039,738 possible combinations of drugs and their components were found 412,575 interacting combinations.
• Medicine section: Standard evidence-based medicine
• The date of the last update of the interaction database: 2026-05-28

Category - medicine